Has John Kriesel, MD received payments from drug or device companies?

Yes. Drug and device makers reported $213 in general payments to John Kriesel, MD across 5 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean John Kriesel, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about John Kriesel, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

John Kriesel, MD

Infectious Disease · Salt Lake City, UTNPI 1780774398

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 94.0% of the total across 5 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 2025 is the largest year on record at $79, 6.2 times the $13 reported in 2019.

$213in general payments, 2019–2025

Across 5 payments — averaging $42.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Merck$108
AbbVie$104

$350,872in research payments, 2019–2025

Across 46 payments — averaging $7627.64 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Biomerieux Inc$108K
Pfizer$98K
Janssen Research & Development, LLC$88K
Sanofi Pasteur Inc.$45K
Biofire Diagnostics, LLC$11K

What the payments were for

Food & beverage$20094%
Education$136%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Merck	3	$108
AbbVie	2	$104

How this compares

$213 in reported general payments places this provider in the 55th percentile of 44 infectious disease providers in Utah.

See all infectious disease providers in Utah →

Medicare billing

Part B allowed, 2024

$17,168

Medicare patients

Services billed

172

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
RukobiaFostemsavir Tromethamine	12	$101,632
BiktarvyBictegrav/Emtricit/Tenofov Ala	16	$92,297
DescovyEmtricitabine/Tenofov Alafenam	33	$73,334
TivicayDolutegravir Sodium	22	$49,519
IsentressRaltegravir Potassium	24	$45,101
EvotazAtazanavir Sulfate/Cobicistat	12	$18,110
Etravirine	18	$15,429
Methenamine Hippurate	34	$2,574
Cephalexin	12	$954
Lamivudine	12	$506
Acyclovir	30	$318
Bupropion XlBupropion Hcl	17	$290
Atorvastatin Calcium	25	$89
Lisinopril	16	$62
Omeprazole	16	$59

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
MerckIsentress	$108	$45,10124 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 44 infectious disease providers in Utah.

Other infectious disease in Salt Lake City

William TettelbachSalt Lake City$82K
Kimberly HansonSalt Lake City$22K
Bert LopansriSalt Lake City$20K
David ClassenSalt Lake City$14K
Andrew SkinnerSalt Lake City$10K
Adam SpivakSalt Lake City$5K
Marquam OliverSalt Lake City$4K
Joel TrachtenbergSalt Lake City$2K
Emily Sydnor SpivakSalt Lake City$1K
Sankar SwaminathanSalt Lake City$800

See the full list for Utah →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →